Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Bevacizumab og Temsirolimus alene eller i kombinasjon med valproinsyre eller cetuximab ved behandling av pasienter med avansert eller metastatisk malignitet eller annen godartet sykdom

3. november 2026 oppdatert av: M.D. Anderson Cancer Center

En fase I-studie av Bevacizumab, Temsirolimus alene og i kombinasjon med valproinsyre, eller Cetuximab hos pasienter med avansert malignitet og andre indikasjoner

This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body or other disease that is not cancerous. Immunotherapy with bevacizumab and cetuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as valproic acid, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bevacizumab and temsirolimus work better when given alone or with valproic acid or cetuximab in treating patients with a malignancy or other disease that is not cancerous.

Studieoversikt

Detaljert beskrivelse

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of treatment with bevacizumab and temsirolimus in combination and plus valproic acid or cetuximab.

SECONDARY OBJECTIVES:

I. Preliminary descriptive assessment of anti-tumor efficacy of each combination.

II. Preliminary assessment of the pharmacokinetic, pharmacodynamic markers of target inhibition and correlates of response (optional).

OUTLINE: This is a dose-escalation study of bevacizumab and temsirolimus. Patients are assigned to 1 of 3 treatment groups.

GROUP I: Patients receive temsirolimus intravenously (IV) over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22.

GROUP II: Patients receive temsirolimus and bevacizumab as in Group I and valproic acid orally (PO) daily on days 1-7 and 15-21.

GROUP III: Patients receive temsirolimus and bevacizumab as in Group I.

In all groups, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Studietype

Intervensjonell

Registrering (Faktiske)

116

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Texas
      • Houston, Texas, Forente stater, 77030
        • M D Anderson Cancer Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or have no standard therapy that induces a complete response of at least 10% or improves survival by at least three months; in addition, patients with disease that are "benign" by pathology, but relentlessly progressive, leading to disability, pain, and premature death in the majority of cases (including, but not limited to lymphangioleiomyomatosis [LAM], type 2 neurofibromatosis [NF], Erdheim Chester disease, and Castleman's disease) may also be considered for enrollment
  • Patients should be at least four weeks from the last day of therapeutic radiation or cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from non-cytotoxic targeted or biologic therapy; patients may have received palliative radiation immediately before (or during) treatment provided radiation is not to the only target lesion available
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Karnofsky >= 60%
  • Lansky performance status of >= 60% for participants 16 years old or younger
  • Absolute neutrophil count >= 1,000/mL
  • Platelets >= 50,000/mL
  • Creatinine =< 3 X upper limit of normal (ULN)
  • Total bilirubin =< 3.0
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 X ULN
  • Fasting level of total cholesterol of no more than 350 mg/dL
  • Triglyceride level of no more than 400 mg/dL
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose
  • Ability to understand and the willingness to sign a written informed consent document
  • Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies

Exclusion Criteria:

  • Patients with clinically significant unexplained bleeding within 28 days prior to entering the study
  • Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg on medication)
  • Patients with clinically significant cardiovascular disease: History of CVA (cerebrovascular accident) within 6 months, myocardial infarction or unstable angina within 6 months, unstable angina pectoris
  • Pregnant or breast-feeding women
  • History of hypersensitivity to bevacizumab, murine products, or any component of the formulation
  • History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation
  • History of hypersensitivity to cetuximab, murine products, or any component of the formulation
  • Patients that are taking cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) inducers and/or inhibitors; if a patient has a history of taking CYP3A4 inducers and/or inhibitors prior to enrollment on the protocol, it is strongly recommended that the patient stops the drug and waits at least 5 half-lives of said drug before initiating therapy on protocol
  • Colorectal cancer patients with known v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (for the arm combining bevacizumab, temsirolimus and cetuximab)
  • Patients who have had major surgery within 6 weeks of enrollment in the study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Group I (temsirolimus, bevacizumab, cetuximab)

Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Given IV

Andre navn:
  • Avastin
  • Anti-VEGF
  • Anti-VEGF humanisert monoklonalt antistoff
  • Anti-VEGF rhuMAb
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar QL 1101
  • Immunoglobulin G1 (Human-mus monoklonal rhuMab-VEGF Gamma-kjede anti-human vaskulær endotelial vekstfaktor), disulfid med human-mus monoklonal rhuMab-VEGF lett kjede, dimer
  • Rekombinant humanisert anti-VEGF monoklonalt antistoff
  • rhuMab-VEGF
  • BEVACIZUMAB, USPESIFISERT LISENSHOLDER

Optional correlative studies

Given IV

Andre navn:
  • Torisel
  • CCI-779
  • CCI-779 Rapamycin Analog
  • Cellesyklushemmer 779
  • Rapamycin Analog
  • Rapamycin Analog CCI-779

Given IV

Andre navn:
  • Erbitux
  • IMC-C225
  • Cetuximab Biosimilar CMAB009
  • Kimerisk anti-EGFR monoklonalt antistoff
  • Kimerisk MoAb C225
  • Kimerisk monoklonalt antistoff C225

Optional correlative studies

Eksperimentell: Group II (temsirolimus, bevacizumab, valproic acid)

Patients receive temsirolimus and bevacizumab as in Group I and valproic acid PO on days 1-7 and 15-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Given IV

Andre navn:
  • Avastin
  • Anti-VEGF
  • Anti-VEGF humanisert monoklonalt antistoff
  • Anti-VEGF rhuMAb
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar QL 1101
  • Immunoglobulin G1 (Human-mus monoklonal rhuMab-VEGF Gamma-kjede anti-human vaskulær endotelial vekstfaktor), disulfid med human-mus monoklonal rhuMab-VEGF lett kjede, dimer
  • Rekombinant humanisert anti-VEGF monoklonalt antistoff
  • rhuMab-VEGF
  • BEVACIZUMAB, USPESIFISERT LISENSHOLDER

Optional correlative studies

Given IV

Andre navn:
  • Torisel
  • CCI-779
  • CCI-779 Rapamycin Analog
  • Cellesyklushemmer 779
  • Rapamycin Analog
  • Rapamycin Analog CCI-779

Optional correlative studies

Given PO

Andre navn:
  • Valproat
  • Depakene
  • Stavzor
Eksperimentell: Group III (temsirolimus, bevacizumab)

Patients receive temsirolimus and bevacizumab as in Group I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Given IV

Andre navn:
  • Avastin
  • Anti-VEGF
  • Anti-VEGF humanisert monoklonalt antistoff
  • Anti-VEGF rhuMAb
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar QL 1101
  • Immunoglobulin G1 (Human-mus monoklonal rhuMab-VEGF Gamma-kjede anti-human vaskulær endotelial vekstfaktor), disulfid med human-mus monoklonal rhuMab-VEGF lett kjede, dimer
  • Rekombinant humanisert anti-VEGF monoklonalt antistoff
  • rhuMab-VEGF
  • BEVACIZUMAB, USPESIFISERT LISENSHOLDER

Optional correlative studies

Given IV

Andre navn:
  • Torisel
  • CCI-779
  • CCI-779 Rapamycin Analog
  • Cellesyklushemmer 779
  • Rapamycin Analog
  • Rapamycin Analog CCI-779

Optional correlative studies

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants With Dose Limiting Toxicities (DLT)
Tidsramme: First 28-day cycle

A dose limiting toxicity (DLT) is defined as a clinically significant adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications and occurring during the first cycle on study that meets any of the following criteria:

  • Grade 3 or 4 non-hematologic toxicity (except nausea and vomiting responsive to appropriate regimens or alopecia)
  • Any Grade 4 hematologic toxicity lasting > 14 days despite supportive measures
  • Any Grade 4 nausea or vomiting > 5 days despite maximum anti-nausea regimens
  • Any other Grade 3 non-hematologic toxicity including symptoms/signs of vascular leak or cytokine release syndrome
  • Any severe or life-threatening complication or abnormality not defined in the NCI-CTCAE that is attributable to the therapy Note: correctable electrolyte imbalances and alopecia are not considered DLTs.
First 28-day cycle

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Sarina A Piha-Paul, M.D. Anderson Cancer Center

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

16. oktober 2012

Primær fullføring (Faktiske)

8. mai 2026

Studiet fullført (Faktiske)

8. mai 2026

Datoer for studieregistrering

Først innsendt

7. mars 2012

Først innsendt som oppfylte QC-kriteriene

12. mars 2012

Først lagt ut (Antatt)

13. mars 2012

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 2012-0061
  • 2012-0061 (Annen identifikator: M D Anderson Cancer Center)
  • NCI-2012-00347 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere